Target type: biologicalprocess
The chemical reactions and pathways resulting in the breakdown of dATP, deoxyadenosine triphosphate (2'-deoxyadenosine 5'-triphosphate). [GOC:go_curators]
The dATP catabolic process is a complex enzymatic pathway responsible for the breakdown of deoxyadenosine triphosphate (dATP), a nucleotide essential for DNA synthesis. This process involves a series of steps, each catalyzed by a specific enzyme.
1. **dATP Deaminase:** The first step is the deamination of dATP by dATP deaminase, an enzyme that removes the amino group from the adenine base of dATP, converting it to deoxyinosine triphosphate (dITP).
2. **dITP Hydrolysis:** dITP is then hydrolyzed by a specific nucleotidase enzyme, which removes the terminal phosphate group, producing deoxyinosine diphosphate (dIDP).
3. **dIDP Hydrolysis:** Another nucleotidase enzyme further hydrolyzes dIDP, removing the remaining phosphate group to generate deoxyinosine monophosphate (dIMP).
4. **dIMP Deoxyribose Removal:** A specialized enzyme called a deoxyribose-phosphate aldolase cleaves the deoxyribose sugar from dIMP, producing hypoxanthine and ribose-1-phosphate.
5. **Hypoxanthine Catabolism:** Hypoxanthine, a purine base, is further catabolized through a series of enzymatic reactions to ultimately generate uric acid, which is excreted from the body.
The dATP catabolic process plays a crucial role in maintaining nucleotide homeostasis, ensuring an appropriate balance of nucleotides for DNA synthesis and other cellular processes. The breakdown of dATP prevents an excessive buildup of this nucleotide, which can lead to various cellular dysfunctions. Moreover, the degradation of dATP provides raw materials for the synthesis of other essential purine nucleotides.'
"
Protein | Definition | Taxonomy |
---|---|---|
Adenosine deaminase | An adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
9-(2-hydroxy-3-nonyl)adenine | 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase | ||
coformycin | coformycins | EC 3.5.4.4 (adenosine deaminase) inhibitor | |
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
nebularine | nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage. nebularine: structure | purine ribonucleoside; purines D-ribonucleoside | fungal metabolite |
9-(2-hydroxy-3-nonyl)adenine | (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | EHNA | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
9-(2-hydroxy-3-nonyl)adenine | (2S,3R)-EHNA : EHNA of absolute configuration 2S,3R. | EHNA | |
1-deazaadenosine | 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source | ||
pentostatin | pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | coformycins | antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor |
8-azanebularine | 8-azanebularine: structure in first source | ||
msh, 4-nle-7-phe-alpha- | polypeptide | dermatologic drug |